[REVISION HISTORY]

mRNA technology and personalized cancer vaccine research

Updated 6 times since CLSTR started tracking revisions of this situation.

What changed

2026-10-26 17:53 UTC → 2026-10-27 00:32 UTC · added ~~removed~~

Recent medical research highlights significant progress in using messenger RNA (mRNA) technology to develop personalized cancer vaccines. These vaccines utilize a patient’s specific tumor mutations or neoantigens to train the immune system to distinguish cancer cells from healthy tissue. Specific developments include reports of mRNA drugs like Daraxonrasib potentially doubling life expectancy for pancreatic cancer patients. In kidney cancer studies, patients with clear cell renal cell carcinoma experienced no recurrence over a three-year median follow-up. Further clinical trials involving the mRNA-based vaccine Intismaran, developed by MSD and Moderna, have shown evolving results. Data from the Phase 3 INTerpath-001 clinical study, presented at the 2026 ESMO Congress in Madrid, involved 1,137 high-risk melanoma patients who had undergone surgical tumor removal. The study shows that adding the personalized vaccine, intismeran autogene, to pembrolizumab immunotherapy reduces the risk of melanoma recurrence or death by 42% and the risk of distant metastasis or death by 38%. Data from a median follow-up of 24.6 months indicated that 82.2% of patients in the combination group remained recurrence-free, compared to 70.0% in the group receiving only standard immunotherapy. A sensitivity analysis showed that for patients who remained cancer-free for the first six months of treatment, the risk of recurrence or death was reduced by 58% in the combination group compared to the monotherapy group. The treatment involves nine doses administered at three-week intervals and is tailored by sequencing tumor DNA to identify up to 34 unique neoantigens. While the clinical results are positive, Moderna shares experienced volatility following the data release as market reactions reflected investor expectations regarding the magnitude of the results.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.